The Lancet Oncology in conversation with
Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.
The Lancet Oncology in conversation with
Yi-Long Wu and Caicun Zhou on non-small-cell lung cancer
Prof Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and Prof Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China) discuss the GEMSTONE 301 and GEMSTONE 302 trials on sugemalimab versus placebo in non-small-cell lung cancer.
Read the full articles:
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301)
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302)
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv